Paclitaxel-eluting balloon versus drug-eluting stent for in-stent restenosis: comparative study of curative effect
10.3969/j.issn.1008-794X.2017.09.016
- VernacularTitle:药物洗脱球囊与药物洗脱支架治疗支架内再狭窄疗效比较
- Author:
Shuyi ZENG
1
;
Zhengdong WANG
;
Jian CHEN
;
Ping LI
;
Wenchao XIE
;
Zhihai LIN
;
Yiyi LI
Author Information
1. 537000,广西 玉林市第一人民医院心血管内科
- Keywords:
drug-eluting balloon;
drug-eluting stent;
in-stent restenosis;
safety;
efficacy
- From:
Journal of Interventional Radiology
2017;26(9):839-842
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the safety and effectiveness of drug-eluting balloon (DEB) with paclitaxel and drug eluting stent (DES) in treating in-stent restenosis (ISR).Methods The clinical data of a total of 76 patients with ISR,who were admitted to authors' hospital to receive stem implantation during the period from January 2012 to September 2014,were retrospectively analyzed.According to the therapeutic means,the patients were divided into paclitaxel DEB group (n=32) and paclitaxel DES group (n=44).The general clinical information and coronary artery angiography findings were collected.The patients were followed up for one year;the all-cause mortality,cardiac death,myocardial infarction,in-stent thrombosis,target lesion revascularization,target vessel revascularization,and major adverse cardiac events were documented.Results No obvious difference in the general data of patients existed between group DEB and group DES (P＞0.05).The incidences of left anterior descending artery ISR in DEB group and in DES group were 43.75％ and 47.73％ respectively.The ISR target vessel types of the two groups were quite similar (P＞0.05).No statistically significant differences in ISR type,ISR lesion type and characteristics of in-stent restenosis existed between the two groups (P＞0.05).One-year following-up examinations indicated that no statistically significant differences in all-cause mortality,cardiac death,myocardial infarction,in-stent thrombosis,target lesion revascularization,target vessel revascularization,and major adverse cardiac events existed between the two groups (P＞0.05).Further analysis revealed that no significant difference in event-free survival existed between the two groups (P＞0.05).Conclusion For the treatment of ISR,the use of paclitaxel DEB is safe and feasible,its curative effect is not less than DES.
